"Pharmaceutical Express" and Platinum Pharmaceuticals listed breaking AbbVie JAK inhibitors up to Phase 3...

December 10, 2020 / Medical Information List and Platinum Pharmaceuticals Hong Kong Stock Exchange first day of trading broke; Pfizer pneumococcal vaccine was eligible for FDA priority review; Lilly GIP/GLP-1 subject agonist Phase 3 clinical results were positive; AbbVie JAK inhibitors reached Phase 3 clinical endpoint ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Hebei to carry out low-value consumables belt procurement December 8, Hebei Provincial Health Insurance Bureau issued "Hebei Province medical supplies centralized belt procurement documents (one-time use of infusions and intravenous retention needles) (draft for comments)."
this procurement variety for the one-time use of infusions medical supplies category, agreed procurement volume by the medical institutions reported in 2021 the actual demand calculation determined.
(Hebei Provincial Health Insurance Bureau) Part 2 was observed and the first day of listing on the Platinum Pharmaceuticals Hong Kong Stock Exchange broke today, and Platinum Pharmaceuticals was officially listed on the main board of the Hong Kong Stock Exchange.
And Platinum Pharmaceuticals opened at HK$11.94, down 3.6 per cent from its offering price.
11 per cent as of the afternoon's close, with the Hong Kong stock market now worth $8,462m.
(Sina Pharmaceutical News) Drug Ming Bio-Energement Arcus developed the best anti-tumor CD39 antibody of its kind today, Pharmaceuticals and Arcus announced the expansion of their strategic partnership.
agreement, Arcus will develop anti-CD39 antibodies using the Pharmaceuticals Bio-Integrated Technology Platform and has exclusive global development and commercial interest in related antibody products.
this is also the fourth antibody project developed by Acus, a pharmaceutical company.
(A.T.) Saishang Pharma completed a $100 million round of A-round financing on December 8, Saisan Pharma announced the official launch and completed a $100 million round of A-round financing, will focus on the development of innovative drugs for patients with central nervous system diseases.
will be used to build and develop the CNS portfolio, with the initial focus on Greater China.
the evening of December 8th, the CSRC announced that it had agreed to the registration of Jiang Biotech's IPO.
According to the previous Jiang Bio prospecto (registration draft), the proposed public offering of shares does not exceed 486.76088 million shares, raising 1.36 billion yuan, mainly used for in-body diagnostic reagent production line upgrade projects, molecular diagnostic engineering research and development center construction projects, marketing and service network upgrade projects, product research and development projects and supplementary liquidity.
(Medical Valley) Remix completed $81 million round of A-round financing recently, Remix announced the completion of $81 million round of A-round financing.
Remix is reprogrammed through RNA processing to treat diseases.
, a technology platform developed by Remix, provides the basis for better drug development.
(Xinhua) -- The Pfizer Pneumococcal vaccine has been approved by the FDA for a biopic license for its 20-price pneumococcal concedes vaccine (20vPnC) to prevent invasive diseases and pneumonia caused by Streptococcus pneumoniae in adults over 18 years of age, Pfizer announced today.
fda also granted priority review of the application and is expected to respond by June next year.
(Pharmaceutical) AbbVie JAK inhibitors reached phase 3 clinical endpoints Today, AbbVie announced that its JAK inhibitor upadacitinib has reached the primary endpoint of clinical remission and all critical secondary endpoints in Phase 3 clinical trials for adult patients treating moderate ulcerative colitis.
in the 8th week of treatment, 26 percent of patients in the upadacitinib group achieved clinical remission, and the placebo group had a 5 percent (p.lt;0.001).
(Sina Pharmaceutical News) Lilly GIP/GLP-1 subject astrogen Phase 3 clinical results positive today, Lilly announced that its GIP/GLP-1 subject two excitant tirzepatide in a phase 3 clinical trial called SURFASS-1 obtained positive top-line results.
after 40 weeks of treatment, tirzepatide significantly reduced glycation hemoglobin levels and weight in adults with type 2 diabetes compared to the placebo group.
(Xinhua) -- Health Canada announced on December 9 that it has approved the emergency use of Pfizer and BioNTech's mRNA-based coronavirus vaccine BNT162b2 (tozinameran) under an interim order, initially recommended for people 16 years of age or older.
Canada became the third country after the United Kingdom and Bahrain to authorize emergency use of the vaccine.
same day, BioNTech said it had learned of the cyberattack from the EMA and that hackers had obtained some vaccine-related documents.
. regulators said they had received two reports of allergic reactions related to the vaccine from Pfizer/BioNTech, according to the Associated Press.
(Xinhua) -- Novarma Kisqal metastatic breast cancer has a median survival period of 5 years, according to Novarma's MONALEESA-7 Phase 3 data released at the annual meeting of SABCS, Kisqali combined endocrine therapy can help women with HR-/HER2-disease have an average median survival of 58.7 months, reducing the risk of death by 24%.
(Sina Pharmaceutical News) INO-4800 clinical trial phase 2 completed the first drug on December 9, INOVIO announced that its new crown candidate vaccine INO-4800 phase 2 trial completed the first subject to the drug.
phase 2 clinical trial is part of a Phase 2/3 clinical trial called the INNOVATE Effectiveness Trial.
(AGENCY) two prescription drugs converted to OTC today, the National Drug Administration issued a sulfate amino glucose bubble tablets and sulfuric acid amino glucose particles two drugs from prescription drugs to over-the-counter drugs announced.
revised, the sulphate amino glucose bubbly tablets with a specification of 0.25 grams (amino glucose sulphate) and 250 mg (amino glucose by sulfate) are all class A OTC drugs.
(Sina Pharmaceutical News) Health Meta Inhalation with Budined mixed suspension to obtain the drug registration certificate today, Health Yuan issued a notice that has received the Approval of the State Drug Administration issued by the inhalation of Budinaid mixed suspension "drug registration certificate."
is a glucodermal hormone that treats asthma with local anti-inflammatory effects.
(Sina Pharmaceutical News) Aachen Pharma announced the latest clinical progress of Bcl-2 inhibitor APG-2575 Today, Aachen Pharma announced its latest clinical progress in the study of the new class 1 drug Bcl-2 inhibitor APG-2575.
data show that more than 30 patients have been included in the clinical study of relapsed/difficult CLL, and the preliminary clinical results show that the objective remission rate in assessable patients reached 70%.
the drug has now been certified as an FDA orphan drug.
(AGENCY) pioneering pharmaceutical ALK-1 antibody joint PD-1 antibody treatment of advanced liver cancer Phase 2 trial results on December 9, Pioneer Pharmaceuticals announced that in 2021 ASCO GI announced that ALK-1 antibody GT90001 joint PD-1 antibody nivolumab second-line treatment of advanced liver cell carcinoma patients phase 2 trial positive data.
results from the first phase of the trial showed that between 9 July 2019 and 30 September 2020, 8 (40%) of the 20 patients assessed observed partial remission and were safe.
(Xinhua) -- A new study published in a new study published in Nature Cancer, a new generation of cancer immunotherapy ISAC, shows that researchers have developed an immune-stimulating antibody concedes (ISAC) that combines the precision of antibody-targeted tumors with the lethal potential of congenital and adaptive immune systems into a single drug, enabling complete tumor receding and long-lasting anti-tumor immunity in multiple tumor models.
that the ISAC drug BDC-1001 presented in this study is being clinically I./II. in patients with HER2 expression tumors.
(Medical Rubik's Cube)